<DOC>
	<DOC>NCT00528112</DOC>
	<brief_summary>This is a study on a new low dose levonorgestrel contraceptive intrauterine systems (LCS). The purpose of the study is to investigate which of the 2 administered doses is the lowest effective intrauterine dose of Levonorgestrel (LNG) administered via the LCS for contraception during 3 years. The study was amended: the LCS16 arm will be extended up to 5 years</brief_summary>
	<brief_title>Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study</brief_title>
	<detailed_description>Drop out-rate will be covered in Participant flow section.</detailed_description>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Age between 18 and 35 years (inclusive), in good general health and requesting contraception. Has regular menstrual cycles (length of cycle 2135 days) (i.e., endogenous cyclicity without hormonal contraceptive use). Known or suspected pregnancy or is lactating. History of ectopic pregnancies. Any genital infection (until successfully treated). Abnormal uterine bleeding of unknown origin.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Intrauterine</keyword>
	<keyword>IUD</keyword>
	<keyword>IUS</keyword>
</DOC>